Multiple Sclerosis (MS) Drug Market

New York Times  10 hrs ago  Comment 
For Michele Lisandrelli, who has multiple sclerosis, traveling the six and a half miles to see her 88-year-old mother has become increasingly difficult.
MedPage Today  Dec 12  Comment 
(MedPage Today) -- A revolution in diagnosis and subsequent monitoring.
MedPage Today  Dec 11  Comment 
(MedPage Today) -- Vitamin D and MS are clearly connected, but do supplements help?
MedPage Today  Dec 8  Comment 
(MedPage Today) -- In this Hot Topics video, three leading clinicians share their approach to treating progressive MS.
GenEng News  Dec 3  Comment 
Servier will team up with GeNeuro to develop and market the experimental multiple sclerosis treatment GNbAC1, the first drug intended to addressing a causal factor of the disease, the companies said today. The deal could generate up to $455...
FierceBiotech  Dec 2  Comment 
Geneva-based GeNeuro, a spinout of the Institut Mérieux, has come up with a licensing deal that will deliver $47 million needed to complete a Phase IIb study of its experimental therapy for multiple sclerosis. And France's Servier gets an option...
Wall Street Journal  Dec 1  Comment 
Novartis said a late-stage study showed little difference between the Swiss pharmaceutical group’s Gilenya drug and a placebo for treating a difficult form of multiple sclerosis.
MedPage Today  Nov 30  Comment 
(MedPage Today) -- Brain growth impairment and thalamic atrophy identified in pediatric multiple sclerosis.
MedPage Today  Nov 19  Comment 
(MedPage Today) -- Research community has progressive multiple sclerosis in its sights.
FierceBiotech  Nov 15  Comment 
Late on Friday the FDA put out the word that it has reversed its earlier decision against Sanofi's multiple sclerosis drug Lemtrada, agreeing to allow the pharma giant the right to market the treatment--with some tight controls on just who will...


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki